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People who use drugs in Toronto have long advocated for access to drug checking in an effort to 
reduce the harms associated with using drugs from the unregulated supply. In 2017, Health Canada 
responded, funding multiple drug checking services across 
the country with the primary goal of preventing overdose. This 
included funding a drug checking pilot in Toronto.
Toronto?s drug checking service launched in October 2019 and 
offers free and anonymous drug checking using mass 
spectrometry technologies (gas- and liquid-chromatography). 
These lab-based technologies offer detailed information 
about which drugs are found in each sample, along with some 
information about how much of each drug is present.
Coordinated by the Centre on Drug Policy Evaluation, this drug 
checking service provides people who use drugs with timely 
and comprehensive information on the composition of their drugs, helping them to make more 
informed decisions. This drug checking service also helps to uncover the contents of Toronto?s 
unregulated drug supply.
Samples are collected at three frontline harm reduction agencies in Toronto, including Parkdale Queen 
West Community Health Centre (Queen West site), South Riverdale Community Health Centre, and The 
Works at Toronto Public Health, where supervised consumption services are offered. However, this 
drug checking service is available to everyone and is not limited to clients of supervised consumption 
services.
Accepted samples include substances (a small amount of powder, a crushed bit of a pill, blotter, or a 
small amount of liquid) and post-use paraphernalia (a used cooker or filter, or leftover liquid from a 
syringe).
Samples are transported to a nearby laboratory at the Centre for Addiction and Mental Health or St. 
Michael?s Hospital where they are analyzed. Results are available within the next business day or two 
and are communicated to clients by harm reduction staff in person or by phone. Along with these 
results, clients receive tailored harm reduction supports, guidance, and referral to services (e.g., 
supervised consumption, naloxone training, primary health care, etc.).
Every two weeks, results from samples checked are combined and disseminated with the goal of 
communicating information about the composition of Toronto?s unregulated drug supply. To receive 
these reports directly, sign up by emailing drugchecking@cdpe.org.
This drug checking service is being scientifically evaluated to understand its impacts on the health and 
well-being of people who use drugs in Toronto. To learn more about the methods and aims of the 
evaluation, read the study protocol and rationale.
Overview of Toronto?s Drug Checking Service
What's the Unregulated 
Drug Supply?
The unregulated drug supply 
includes illegal drugs, as well 
as legal drugs diverted from 
regulated markets for sale 
through criminal channels. 
4
Drug name Description
2C class drugs A family of psychedelic drugs
3-FA An active amphetamine-related drug
6-MAM An active heroin-related drug
Acetyl fentanyl An active fentanyl-related drug
AEME An inactive cocaine-related drug
Alprazolam (Xanax) A medication used to treat anxiety
Amantadine A medication used to treat influenza A infections and 
Parkinson?s disease
AMB-FUBINACA An ?ultrapotent? synthetic cannabinoid
Benzoylecgonine An inactive cocaine-related drug
Carfentanil An ?ultrapotent? fentanyl-related drug
Citalopram A medication used to treat depression
Despropionyl fentanyl (4-ANPP) An inactive fentanyl-related drug, which is an impurity found in 
fentanyl preparations 
DOI A potent psychedelic drug
Doxepin A medication used to treat depression and anxiety
Etizolam An active benzodiazepine-related drug
Fentanyl (hydroxy) An inactive fentanyl-related drug
Flualprazolam An active benzodiazepine-related drug
Flubromazolam An active benzodiazepine-related drug
Furanyl UF-17 An opioid-related drug with unknown potency and effects
Levamisole A medication used to treat worm infections in animals, pulled 
from the Canadian market in the early 2000s
Methylecgonine An inactive cocaine-related drug
Norfentanyl An inactive fentanyl-related drug
Phenacetin A pain-relieving, fever-reducing medication, pulled from the 
Canadian market in the 1970s for its association with kidney 
and bladder cancers
Tropacocaine An inactive cocaine-related drug
Drug Dictionary
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Results from Samples Checked
October 10, 2019 ? March 31, 2020
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Between October 10, 2019, when Toronto?s drug checking service formally launched, and March 31, 
2020:
- 543 samples were checked, including substances (63%) and post-use paraphernalia (37%).
- On average, 25 samples were checked each week.
- 46% of the samples checked were expected to be fentanyl.
- Fentanyl was found in 93% of the samples that were expected to be fentanyl.
- When other drugs were found with fentanyl, caffeine (87%) was most common.
- 43% of expected heroin samples contained no heroin.
- 96% of expected cocaine samples contained cocaine and other drugs, although other drugs most 
commonly found were cocaine-related.
- Samples expected to be opioids were more contaminated than other expected drug types ? 
meaning there were a lot of other drugs found in each expected opioid sample. For example, 6% of 
expected fentanyl samples contained only fentanyl, while:
- 86% of expected methamphetamine samples contained only methamphetamine.
- 44% of expected MDMA samples contained only MDMA.
- 77% of expected ketamine samples contained only ketamine.
- Unexpected noteworthy drugs were often found in Toronto?s drug supply. For example:
- Benzodiazepines and benzodiazepine-related drugs, 
like etizolam, flualprazolam, flubromazolam, and 
alprazolam, were unexpectedly found in 36% of 
expected fentanyl samples, which led to the issuance 
of an alert by Toronto Public Health given their 
presence and associated complications in overdose 
events.
- AMB-FUBINACA was unexpectedly found in 3% of 
expected fentanyl samples.
- Carfentanil was unexpectedly found in 1% of expected 
fentanyl samples.
- Fentanyl was unexpectedly found in 43% of expected 
heroin samples.
- Levamisole was unexpectedly found in 14% of expected cocaine samples.
Key Findings
What are Notewor thy 
Drugs?
?Noteworthy drugs? are drugs 
that are highly potent, linked 
to overdose or other adverse 
effects, or may not be desired 
by some clients. Noteworthy 
drugs are called out when 
they are unexpectedly found 
in checked samples.
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Two types of samples are accepted by this drug checking service: substances (a small amount of 
powder, a crushed bit of a pill, blotter, or a small amount of liquid) and post-use paraphernalia (a used 
cooker or filter, or leftover liquid from a syringe).
Between October 10, 2019, and March 31, 2020, 543 samples were checked: 63% (344) were 
substances and 37% (199) were post-use paraphernalia.
Checked Samples by Sample Type
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When a client submits a sample to be checked, they indicate which drug they expect that sample to 
contain. The following shows which drugs were expected for the 543 samples checked between 
October 10, 2019, and March 31, 2020.
Other expected drugs included: 3 MEO-PCE, 4-AcO-DET, 4-AcO-DMT, 4-AcO-MET, 4-FA, 4-HO-MET, 
4-HO-MiPT, 5-APB, 5-MeO-DiPT, 5-MeO-DMT, 5-MeO-MIPT, ADMK4, AMT, caffeine, DMT, freebase DMT, 
fumarate DOM, down, DPT, etaqualone, GHB, HDIK4, MDA, mescaline, methandrostenolone, MIPLA, 
modafinil, O-desmethyltramadol, O-PCE, Percocet, testosterone enanthate, tsunami, Viagra, and Z drug.
Unknown includes samples that did not have a stated expected drug.
Polysubstance includes samples that had two or more expected drugs (e.g., fentanyl and 
methamphetamine).
Checked Samples by Expected Drug
9
Of the 543 samples checked between October 10, 2019, and March 31, 2020, 46% (252) were expected 
to be fentanyl (36% were substances and 64% were post-use paraphernalia).
Expected Fentanyl Samples
Presence of fentanyl in expected fentanyl samples (252)
Expected fentanyl samples containing fentanyl and other drugs (219)
In samples expected to be fentanyl that contained no fentanyl, the most commonly found drugs 
included: caffeine, methamphetamine, cocaine, hydromorphone, and naproxen.
Note: More than one drug may be found in each sample so percentages may add up to more than 100%.
Opioids
Of the 252 samples expected to be fentanyl, 87% (219) contained fentanyl and other drugs. The 
following shows which other drugs were found in expected fentanyl samples that contained fentanyl 
and other drugs and in what number of samples.
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?Noteworthy drugs? are drugs that are highly potent, linked to overdose or other adverse effects, or may 
not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in 
checked samples. Of the 252 samples expected to be fentanyl, unexpected noteworthy drugs found 
included:
- 56% (141) of expected fentanyl samples contained despropionyl fentanyl (4-ANPP)
- 36% (91) of expected fentanyl samples contained one or more benzodiazepine or 
benzodiazepine-related drug:
- 33% (83) of expected fentanyl samples contained etizolam
- 15% (37) of expected fentanyl samples contained flualprazolam
- 1% (3) of expected fentanyl samples contained flubromazolam
- 1% (2) of expected fentanyl samples contained alprazolam
- 13% (33) of expected fentanyl samples contained phenacetin
- 7% (17) of expected fentanyl samples contained acetyl fentanyl
- 6% (15) of expected fentanyl samples contained fentanyl (hydroxy)
- 5% (13) of expected fentanyl samples contained furanyl UF-17
- 3% (8) of expected fentanyl samples contained norfentanyl
- 3% (7) of expected fentanyl samples contained AMB-FUBINACA
- 1% (2) of expected fentanyl samples contained carfentanil
Unexpected noteworthy drugs in expected fentanyl samples (252)
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 1% (7) were expected to 
be heroin (57% were substances and 43% were post-use paraphernalia).
Expected Heroin Samples
Presence of heroin in expected heroin samples (7)
Expected heroin samples containing heroin and other drugs (4)
In samples expected to be heroin that contained no heroin, the most commonly found drugs included: 
6-MAM (heroin-related), caffeine, codeine, morphine, fentanyl, and phenacetin.
Note: More than one drug may be found in each sample so percentages may add up to more than 100%.
Of the 7 samples expected to be heroin, 57% (4) contained heroin and other drugs. The following 
shows which other drugs were found in expected heroin samples that contained heroin and other drugs 
and in what number of samples.
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?Noteworthy drugs? are drugs that are highly potent, linked to overdose or other adverse effects, or may 
not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in 
checked samples. Of the 7 samples expected to be heroin, unexpected noteworthy drugs found 
included:
- 43% (3) of expected heroin samples contained fentanyl
- 43% (3) of expected heroin samples contained phenacetin
- 29% (2) of expected heroin samples contained despropionyl fentanyl (4-ANPP)
Unexpected noteworthy drugs in expected heroin samples (7)
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 1% (4) were expected to 
be carfentanil (75% were substances and 25% were post-use paraphernalia).
Expected Carfentanil Samples
Presence of carfentanil in expected carfentanil samples (4)
Unexpected noteworthy drugs in expected carfentanil samples (4)
In samples expected to be carfentanil that contained no carfentanil, the most commonly found drugs 
included: fentanyl, despropionyl fentanyl (4-ANPP), and furanyl UF-17.
?Noteworthy drugs? are drugs that are highly potent, linked to overdose or other adverse effects, or may 
not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in 
checked samples. Of the 4 samples expected to be carfentanil, unexpected noteworthy drugs found 
included:
- 75% (3) of expected carfentanil samples contained fentanyl
- 25% (1) of expected carfentanil samples contained despropionyl fentanyl (4-ANPP)
- 25% (1) of expected carfentanil samples contained furanyl UF-17
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 9% (51) were expected to 
be cocaine (96% were substances and 4% were post-use paraphernalia).
Expected Cocaine Samples
Presence of cocaine in expected cocaine samples (51)
Expected cocaine samples containing cocaine and other drugs (49)
In samples expected to be cocaine that contained no cocaine, the most commonly found drugs 
included: acetaminophen.
Stimulants
Of the 51 samples expected to be cocaine, 96% (49) contained cocaine and other drugs. Other drugs 
found included:
- 90% (44) of expected cocaine samples contained benzoylecgonine (cocaine-related)
- 16% (8) of expected cocaine samples contained AEME (cocaine-related)
- 16% (8) of expected cocaine samples contained phenacetin
- 14% (7) of expected cocaine samples contained levamisole
Note: More than one drug may be found in each sample so percentages may add up to more than 100%.
Unexpected noteworthy drugs in expected cocaine samples (51)
?Noteworthy drugs? are drugs that are highly potent, linked to overdose or other adverse effects, or may 
not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in 
checked samples. Of the 51 samples expected to be cocaine, unexpected noteworthy drugs found 
included:
- 16% (8) of expected cocaine samples contained phenacetin
- 14% (7) of expected cocaine samples contained levamisole
15
Of the 543 samples checked between October 10, 2019, and March 31, 2020, 8% (42) were expected to 
be methamphetamine (86% were substances and 14% were post-use paraphernalia).
Expected Methamphetamine Samples
Presence of methamphetamine in expected methamphetamine samples (42)
Expected methamphetamine samples containing methamphetamine and other drugs (3)
In samples expected to be methamphetamine that contained no methamphetamine, the most 
commonly found drugs included: cocaine and AEME (cocaine-related).
Of the 42 samples expected to be methamphetamine, 7% (3) contained methamphetamine and other 
drugs. Other drugs found included:
- 67% (2) of expected methamphetamine samples contained cocaine
- 67% (2) of expected methamphetamine samples contained benzoylecgonine (cocaine-related)
Note: More than one drug may be found in each sample so percentages may add up to more than 100%.
Unexpected noteworthy drugs in expected methamphetamine samples (42)
?Noteworthy drugs? are drugs that are highly potent, linked to overdose or other adverse effects, or may 
not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in 
checked samples. Of the 42 samples expected to be methamphetamine, unexpected noteworthy drugs 
found included:
- 5% (2) of expected methamphetamine samples contained fentanyl
- 2% (1) of expected methamphetamine samples contained despropionyl fentanyl (4-ANPP)
- 2% (1) of expected methamphetamine samples contained phenacetin
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 2% (9) were expected to 
be crack (56% were substances and 44% were post-use paraphernalia).
Expected Crack Samples
Presence of cocaine in expected crack samples (9)
Expected crack samples containing cocaine and other drugs (8)
In samples expected to be crack that contained no cocaine, the most commonly found drugs included: 
oxycodone.
Of the 9 samples expected to be crack, 89% (8) contained cocaine and other drugs. Other drugs found 
included:
- 50% (4) of expected crack samples contained methylecgonine (cocaine-related)
- 38% (3) of expected crack samples contained benzoylecgonine (cocaine-related)
- 38% (3) of expected crack samples contained tropacocaine (cocaine-related)
- 25% (2) of expected crack samples contained AEME (cocaine-related)
- 25% (2) of expected crack samples contained phenacetin
Note: More than one drug may be found in each sample so percentages may add up to more than 100%.
Unexpected noteworthy drugs in expected crack samples (9)
?Noteworthy drugs? are drugs that are highly potent, linked to overdose or other adverse effects, or may 
not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in 
checked samples. Of the 9 samples expected to be crack, unexpected noteworthy drugs found 
included:
- 22% (2) of expected crack samples contained phenacetin
- 11% (1) of expected crack samples contained fentanyl
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 1% (6) were expected to 
be amphetamine (all were substances).
Expected Amphetamine Samples
Presence of amphetamine in expected amphetamine samples (6)
In samples expected to be amphetamine that contained no amphetamine or contained amphetamine 
and other drugs, the most commonly found drugs included: methamphetamine.
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 5% (27) were expected to 
be MDMA (all were substances).
Expected MDMA Samples
Presence of MDMA in expected MDMA samples (27)
Expected MDMA samples containing MDMA and other drugs (6)
In samples expected to be MDMA that contained no MDMA, the most commonly found drugs included: 
MDA and caffeine.
Psychedelics
Of the 27 samples expected to be MDMA, 22% (6) contained MDMA and other drugs. Other drugs 
found included:
- 67% (4) of expected MDMA samples contained MDA
- 33% (2) of expected MDMA samples contained acetaminophen
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 3% (15) were expected to 
be a 2C class drug (all were substances).
Expected 2C class drugs included 2C-B, 2C-C, 2C-D, 2C-E, 2C-I, 2C-P, and 2C-T-2.
Expected 2C Class Samples
Presence of 2C class drugs in expected 2C class samples (15)
Expected 2C class samples containing 2C class drugs and other drugs (8)
In samples expected to be a 2C class drug that contained no 2C class drug, the most commonly found 
drugs included: ketamine and caffeine.
Of the 15 samples expected to be a 2C class drug, 53% (8) contained a 2C class drug and other drugs. 
Other drugs found included:
- 50% (4) of expected 2C class drug samples contained an unknown 2C class-related drug
- 38% (3) of expected 2C class drug samples contained citalopram
- 25% (2) of expected 2C class drug samples contained ketamine
Note: More than one drug may be found in each sample so percentages may add up to more than 100%.
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 2% (13) were expected to 
be ketamine (all were substances).
Expected Ketamine Samples
Presence of ketamine in expected ketamine samples (13)
Expected ketamine samples containing ketamine and other drugs (2)
In samples expected to be ketamine that contained no ketamine, the most commonly found drugs 
included: MDMA.
Of the 13 samples expected to be ketamine, 15% (2) contained ketamine and other drugs. Other drugs 
found included:
- 50% (1) of expected ketamine samples contained 3-FA
- 50% (1) of expected ketamine samples contained acetaminophen
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 2% (10) were expected to 
be LSD (all were substances).
Expected LSD Samples
Presence of LSD in expected LSD samples (10)
In samples expected to be LSD that contained no LSD, the most commonly found drugs included: DOI.
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Of the 543 samples checked between October 10, 2019, and March 31, 2020, 3% (16) were expected to 
be a benzodiazepine or a benzodiazepine-related drug (all were substances).
Expected benzodiazepine and benzodiazepine-related drugs included alprazolam, etizolam, 
flualprazolam, and flubromazolam.
Expected Benzodiazepine Samples
Presence of benzodiazepines and benzodiazepine-related drugs in expected 
benzodiazepine samples (16)
Expected benzodiazepine samples containing a benzodiazepine or benzodiazepine-related 
drug and other drugs (9)
Depressants
Of the 16 samples expected to be a benzodiazepine or benzodiazepine-related drug, 56% (9) contained 
a benzodiazepine or benzodiazepine-related drug. Other drugs found included:
- 44% (4) of expected benzodiazepine samples contained caffeine
- 33% (3) of expected benzodiazepine samples contained amantadine
- 33% (3) of expected benzodiazepine samples contained doxepin
- 22% (2) of expected benzodiazepine samples contained hydromorphone
Note: More than one drug may be found in each sample so percentages may add up to more than 100%.
Unexpected noteworthy drugs in expected benzodiazepine samples (16)
?Noteworthy drugs? are drugs that are highly potent, linked to overdose or other adverse effects, or may 
not be desired by some clients. Noteworthy drugs are called out when they are unexpectedly found in 
checked samples. Of the 16 samples expected to be a benzodiazepine, unexpected noteworthy drugs 
found included:
- 6% (1) of expected benzodiazepine samples contained fentanyl
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It is important to understand the limitations of this drug checking service:
1. Checking a sample cannot guarantee that a drug is safe to use.
2. The results from a sample may not represent the rest of the drugs that sample was taken from. This 
is known as the Chocolate Chip Cookie Effect.
3. There are technological limitations:
a. Some drugs may be missed.
b. Non-drug fillers are not reported. This could include 
non-drug fillers that may be dangerous, such as 
bacteria, metals, pesticides, or inorganic salts. Other 
non-drug fillers may not be dangerous, such as sugar 
or laxatives.
4. Results for samples that are taken from post-use 
paraphernalia have other limitations:
a. Paraphernalia, like cookers, are often re-used. The 
mass spectrometry technologies used for this drug 
checking service (gas- and liquid-chromatography) 
are so sensitive that very trace amounts of drugs may 
be found. This means that when paraphernalia is 
re-used, drugs from past use may present in the 
results for the sample that is being checked.
b. Fatty acids are more commonly found in samples 
that are taken from post-use paraphernalia, most 
likely from oils on skin. These fatty acids can interfere 
with the mass spectrometry analysis. It may be difficult to see past them to determine which 
drugs are present.
For these reasons, checking substances instead of post-use paraphernalia is preferred.
Limitations of Toronto?s Drug Checking Service
What's the Chocolate Chip 
Cookie Effect?
The results for a sample that 
is checked may not represent 
the rest of the drugs that 
sample was taken from. You 
can imagine your drugs as a 
chocolate chip cookie. If you 
check a piece of the cookie 
that is only dough, your 
results may not identify 
chocolate as present. Mixing 
a powder or scratching 
different parts of a pill when 
preparing a sample can 
increase the 
representativeness of your 
sample.
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Special thanks from the Centre on Drug Policy Evaluation to the Community Advisory Board, a group of 
ten people who use drugs in Toronto that meet monthly to consult on the design and execution of this 
drug checking service.
We also wish to thank our funders, partners, and collaborators for their ongoing commitment to 
Toronto?s drug checking service:
- British Columbia Centre of Substance Use
- Centre for Addiction and Mental Health
- Health Canada?s Drug Analysis Service
- Health Canada?s Substance Use and Addictions Program
- Moss Park Consumption & Treatment Service
- Office of the Chief Coroner for Ontario
- Ontario Harm Reduction Network
- Ontario Poison Centre
- Parkdale Queen West Community Health Centre
- Public Health Ontario
- Sandy Hill Community Health Centre
- South Riverdale Community Health Centre
- St. Michael?s Hospital
- St. Michael?s Hospital Foundation
- Street Health
- The Works at Toronto Public Health
- Toronto Harm Reduction Alliance
- Toronto Paramedic Services
- Toronto Public Health
- Trip! Project
We wish to remember all the lives that have been lost ? both in the ongoing overdose crisis and long 
before ? due to a lack of regulation of the drugs described herein. Our work is dedicated to the 
community members who are no longer with us, including those who directly contributed to this 
project. May their deaths not have been in vain.
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The Centre on Drug Policy Evaluation strives to improve community health and safety by conducting 
research and outreach on best practices in drug policy. We work collaboratively with governments, 
affected communities, and civil society to guide effective and evidence-based policy responses to 
substance use. The Centre on Drug Policy Evaluation is now housed within the Li Ka Shing Knowledge 
Institute at St. Michael?s Hospital, a site of Unity Health Toronto, in Toronto, Canada.
Learn more about Toronto?s drug checking service. Like us on Facebook, 
facebook.com/centreondrugpolicyevaluation, and follow us on Twitter, @drugpolicyctr.
Questions or comments? We?d love to hear from you. You can reach us at drugchecking@cdpe.org.
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